CA1093999A - Antibiotic bl580.delta. from streptomyces hygrosicopieus - Google Patents
Antibiotic bl580.delta. from streptomyces hygrosicopieusInfo
- Publication number
- CA1093999A CA1093999A CA279,775A CA279775A CA1093999A CA 1093999 A CA1093999 A CA 1093999A CA 279775 A CA279775 A CA 279775A CA 1093999 A CA1093999 A CA 1093999A
- Authority
- CA
- Canada
- Prior art keywords
- antibiotic
- column
- delta
- ethyl acetate
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 29
- 241000187747 Streptomyces Species 0.000 title description 3
- 241000187391 Streptomyces hygroscopicus Species 0.000 claims abstract description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 abstract description 9
- 230000004151 fermentation Effects 0.000 abstract description 9
- 229940124536 anticoccidial agent Drugs 0.000 abstract description 3
- 239000003224 coccidiostatic agent Substances 0.000 abstract description 3
- 230000002906 microbiologic effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 64
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 229940093499 ethyl acetate Drugs 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 24
- 239000002609 medium Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- 239000012071 phase Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000002054 inoculum Substances 0.000 description 13
- 159000000000 sodium salts Chemical class 0.000 description 13
- 239000005909 Kieselgur Substances 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 9
- 229940073584 methylene chloride Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- -1 amine cations Chemical class 0.000 description 7
- 244000144977 poultry Species 0.000 description 7
- 235000013594 poultry meat Nutrition 0.000 description 7
- 210000004215 spore Anatomy 0.000 description 7
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 235000010419 agar Nutrition 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000005273 aeration Methods 0.000 description 5
- 229940076134 benzene Drugs 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000223931 Eimeria acervulina Species 0.000 description 4
- 241000223932 Eimeria tenella Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000224483 Coccidia Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000499566 Eimeria brunetti Species 0.000 description 2
- 241000223934 Eimeria maxima Species 0.000 description 2
- 241000499563 Eimeria necatrix Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- PYMYPHUHKUWMLA-VPENINKCSA-N aldehydo-D-xylose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VPENINKCSA-N 0.000 description 2
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 2
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 2
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N keto-D-fructose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 210000003250 oocyst Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 2
- 229940120668 salicin Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940032330 sulfuric acid Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- POJDZWIPNZWPAU-UHFFFAOYSA-N 2-methyl-1-nitro-3-nitrosoguanidine Chemical compound O=NNC(=NC)N[N+]([O-])=O POJDZWIPNZWPAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241001486585 Bimeria Species 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000116484 Inula helenium Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241000544912 Melanoides Species 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000010699 lard oil Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229940080839 methionine 500 mg Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
This disclosure describes a new antibiotic desig-nated BL580.DELTA. produced in a microbiological fermentation under controlled conditions using a new strain of Streptomyces hygroscopicus and mutants thereof. This new antibiotic is an active anticoccidial agent.
This disclosure describes a new antibiotic desig-nated BL580.DELTA. produced in a microbiological fermentation under controlled conditions using a new strain of Streptomyces hygroscopicus and mutants thereof. This new antibiotic is an active anticoccidial agent.
Description
26,293 10~399~
This invention relates to a new antibiotic designated BL580~, to its production by fermentation, to methods for its recovery and concentration from crude solutions and to processes for its purification. The ~-present invention includes within its scope the antibi-otic BL580~ in dilute form, as a crude concentrate and in its pure crystalline form. The effects of this new an~ibiotic as an anticoccidial agent together with its chemical and physical properties, differentiate it from previously described antibiotics.
Antibiotic B1580~ may be represented by the following structural formula which is in accordance with accepted convention in that an a-substituent is behind the plane of the paper and is represented by a ---- bond whereas a ~-substituent is in front of the plane of the paper and is represented by a _ bond.
This invention relates to a new antibiotic designated BL580~, to its production by fermentation, to methods for its recovery and concentration from crude solutions and to processes for its purification. The ~-present invention includes within its scope the antibi-otic BL580~ in dilute form, as a crude concentrate and in its pure crystalline form. The effects of this new an~ibiotic as an anticoccidial agent together with its chemical and physical properties, differentiate it from previously described antibiotics.
Antibiotic B1580~ may be represented by the following structural formula which is in accordance with accepted convention in that an a-substituent is behind the plane of the paper and is represented by a ---- bond whereas a ~-substituent is in front of the plane of the paper and is represented by a _ bond.
2 ~r ~` ` 10S~999 S S~
~o , ~
~ \o ~o o~
o o~
\~
~~
1(~5 3'39~
According to the present invention there is provided a process for the preparation of antibiotic BL580~ of the formula:
Cll~O. CH3 ~ 3 :
~0 Cg,~ ' and the pharmacologically acceptable cationic salts thereof, which comprises cultivating Streptomyces hygroscopicus NRRL 8180 or mutants thereof in an aqueous nutrient medium containing assimilable sources of carbohydrate, nitrogen, and inorganic salts under submerged aerobic conditions until substantial antibiotic activity is imparted to said medium, and then reeovering antibiotic BL580~therefrom.
The novel antibiotic of the present invention is an organic carboxylic acid and thus is capable of forming salts with non-toxic, pharmaceutically acceptable cations. Thus, salts formed by admixture of the antibiotic free acid with stoichiometric amounts of cations, suitably in a neutral solvent, may be formed with cations such as the sodium ion, potassium ion, calcium ion, magnesium ion, and ammonium ion as well as the organic amine cations such as the tri ~lower alkyl) amine cations (e.g. triethylamine, triethanolamine), procaine, and the li~e. The cationic salts of antibiotic BL580~ are, in general, crystalline solids, relatively insoluble in water, and soluble in most common organic solvents such as methanol, ethyl acetate, acetone, chloroform, heptane, ether, and benzene.
The new antibiotic which has been designated BL580~ is formed during the cultivation under controlled conditions of a new strain of aJ
9~
Streptomyces hygroscopicus which also produces the known anti-biotics BL580~ and BL580~ (see United States Patent No. 3,812,249).
This new strain is a mutant derived by treatment of S. hygrosco-picus NRRL 5647 with N-methyl-N'-nitro-N"-nitrosoguanidine. A
~iable culture of the new microorganism has been deposited with the Culture Collection Laboratory, Northern Utilization Research and Development Division, United States Department of Agriculture, Peoria, Illinois, and has been added to its permanent collection.
It is freely available to the public from this depository under its accession number NRRL 8180.
The cultural, physiological and morphological - 4a -.-.5 : ., .
: ~ . :
1~3999 1 features of NRRL 8180 are substantially the same as those of NRRL 5647 as determined by Dr. H.D. Tresner, Lederle Laboratories Division, American Cyanamid Company, Pearl River, New York. The general description of the microorganism, based on diagnostic characteristics ob-served, is the same as that for NRRL 5647 published in United States Patent No. 3,812,249, but is reproduced below for convenience.
Observations were made of the cultural, phys-iological and morphological features of NRRL 8180 in accordance with the methods detailed by Shirling and Gottlieb, Internat. Journ. of Syst. Bacteriol., 16, 313--340 (1966). The underscored descriptive colors and color chip designations are taken from Jacobson, et al., Color Harmony Manual, 3rd Edition (1948), Container Corp.
of America, Chicago, Illinois. Descriptive details are recorded in Tables I through IV below.
Amount of Growth Good on yeast extract, Kuster's oatflake, tomato paste-oatmeal and potato-dextrose agars; moderate on aspargine-dextrose, Hickey and Tresner's, inorganic salts-starch and Bennett's agars; light on Czapek's so-lution agar.
Aerial Mycelium Whitish to yellowish, becoming grayish in sporula-tion zone~ ranging from Fawn (4 ig) to Beaver (4 li) to A~hes (5 fe). Sporulation zones becoming black and hygroscopic in older cultures.
Soluble Pigments None on most media; yellowish on yeast extract, : - .;., ~ . ~
. ~ , 1~39~
1 Bennett's and potato-dextrose agars and only in light amounts.
Reverse Color Generally in yellowish shades on most media.
5 Miscellaneou~ Physiological Reactions Nitrates reduced to nitrites; complete liquefaction of gelatin; no formation of melanoid pigments on peptone--iron agar; complete peptonization of purple milk in 7 days; tolerance of NaCl in growth medium > 7 percent but ~ 10 percent. Carbon source utilization according to the method of ~ridham and Gottlieb, J. Bacteriol., _, 107-114 (1948) as follows: Good utilization of adon-itol, d-galactose, d-fructose, d-raffinose, salicin, d-xylose and dextrose; poor or no utilization of d-melezi-tose, d-melibiose, l-arabinose, i-inositol, lactose, d-mannitol, l-rhamnose, sucrose and d-trehalose.
Micromorpholog~
Aerial mycelium gives rise to spore-bearinc branches which terminate in tightly coiled spirals of several turns; pores are mostly isodiametric, cylindrical, phalangiform, 0.6-0.7~m x 0.7-0.8,um. Spores smooth as determined by electron microscopy; ~pore sheaths finely wrinkled.
On the basis of the general characteristics observed, microorganism NRRL 8180 is a member of a large group of streptomycetes characterized by gray spores, spiral spore chains, smooth-walled spores and lack of melanin pigments. The hygroscopic nature of the culture along with its entire composite of morphological and physiological characteristics makes it a representative 39~9 strain of Streptomyces hygroscopicuc as defined by H.
D. Tresner and E. J. Backus, "A Broadened Concept of the Characteristics of Streptomyces hygroscopicus", Appl. Microbiol., 4, 243-250 (1956) and ~. D. Tresner, 5 E. J. Backus and J. A. Hayes, "Morphological Spore Types in the Streptomyces hygroscopicus-like Complex", Appl.
Microbiol., 15, 637 639 (1967).
~0 39~
U U ~, ~U
~ . _~ O ,, ~ C _~
~ ~ Vc ~ L~ Vc U~
V Ll .C U o C U C. N O
9~ C C N C C N 11) _1 C C N
Vl o '~'~ ,a C,0~5, ~ U) o u ~ ~ 8 ~ ~ u O h O _ ~
~ U ~ _ ~ ~ _ z ~ ~o 8 v N oo ,u~l ~03 ~ C lal ~
~ .. _ .
O . ~V~ ~r ~ ~ tl C 0'~ O C C . C , U~ ~ ~.rl __ _.. _.
v . ~ . 0 ~ ~:
8 ~ V ~ I ~C I I ,~ O
E~ ~ e, .~ v ~ v ~ O ~ v u ~ ~
q.l .,1 U r~ C3 ~ 'C ~ ~ 3 ul 8 o~ e E ~ ,c u~ ~ ~ v u E ,~ v ''~ 3-ek Vi ~ 3k; ul .,.~ 1 v 1~ .3 v u ~t c ~ 1~ u ~UJ ~ OD.
.~ ~ ~ ~ ~ e ~r ON ~0 e ~ ON e -~ u' vu 16 ~ o ,~ O c ~ o~e ~ ~
~a u u vl r~ o :~ ~ c r~ o ~ .~ e ~ o c ~ .
_ ~ ~o ~ ~ v o 5 u ~ o ~ ~ ~
I~J V'3 V V
V 3 C ~3 O - . ~:
:' _ ,0 .~ .. ___ ~1 ~ V~U ~ X .
C .~ .~ ~X O C
h U~ ),~ ~1 C ,a Id ~ ~ Ul ~ U~ ~ ~ ~
10~ 9~9 ~ ~ o ~ j:
xoo ~L'8 ~uo~ ~8 o 8 ~ ~ ~i e A I l 1~ 3 ~ 1~ ¦
_ ~1 8 :~ 3c ~c u o~ ~.~
v ! be St~ Zb-~ cs ~ ~a o~ 2~ 0 ~ ~ o ~ ~c` o~ ~ 5 c-V~
~ ~ o ~ ~ l ~
~ c ~ ~ ~ c~i ~ ~ i Y
- -- 9 - :
1~399~
U U
o~ Q~,, 0 h ~) .
~ r~C S~ ~
td ~1 .C C N
~ ~t: ,0 1~ ~
~ O ~ O
oE~
~ i ' 00 ~ .C`
~ ~ i) 3 ~ ~ : ~ , ~ .
.~ ~ O I
~ O ,CSI~rlO
H~ . ~ ~ ~
~1 u~ ~ 1 3 C ~r 0 nO ~ O.~ .
~a t~ ~ 1~ E~ C
E~ 0 ~ ul :~ O ~ O
O Ei~1 U ;~ N (O
~0 la ~ a) ,q ~ c~ , .~ '~ ~ ~0 'J~ EOi~
~ a~ ~ .,~ ~
~o , ~
~ \o ~o o~
o o~
\~
~~
1(~5 3'39~
According to the present invention there is provided a process for the preparation of antibiotic BL580~ of the formula:
Cll~O. CH3 ~ 3 :
~0 Cg,~ ' and the pharmacologically acceptable cationic salts thereof, which comprises cultivating Streptomyces hygroscopicus NRRL 8180 or mutants thereof in an aqueous nutrient medium containing assimilable sources of carbohydrate, nitrogen, and inorganic salts under submerged aerobic conditions until substantial antibiotic activity is imparted to said medium, and then reeovering antibiotic BL580~therefrom.
The novel antibiotic of the present invention is an organic carboxylic acid and thus is capable of forming salts with non-toxic, pharmaceutically acceptable cations. Thus, salts formed by admixture of the antibiotic free acid with stoichiometric amounts of cations, suitably in a neutral solvent, may be formed with cations such as the sodium ion, potassium ion, calcium ion, magnesium ion, and ammonium ion as well as the organic amine cations such as the tri ~lower alkyl) amine cations (e.g. triethylamine, triethanolamine), procaine, and the li~e. The cationic salts of antibiotic BL580~ are, in general, crystalline solids, relatively insoluble in water, and soluble in most common organic solvents such as methanol, ethyl acetate, acetone, chloroform, heptane, ether, and benzene.
The new antibiotic which has been designated BL580~ is formed during the cultivation under controlled conditions of a new strain of aJ
9~
Streptomyces hygroscopicus which also produces the known anti-biotics BL580~ and BL580~ (see United States Patent No. 3,812,249).
This new strain is a mutant derived by treatment of S. hygrosco-picus NRRL 5647 with N-methyl-N'-nitro-N"-nitrosoguanidine. A
~iable culture of the new microorganism has been deposited with the Culture Collection Laboratory, Northern Utilization Research and Development Division, United States Department of Agriculture, Peoria, Illinois, and has been added to its permanent collection.
It is freely available to the public from this depository under its accession number NRRL 8180.
The cultural, physiological and morphological - 4a -.-.5 : ., .
: ~ . :
1~3999 1 features of NRRL 8180 are substantially the same as those of NRRL 5647 as determined by Dr. H.D. Tresner, Lederle Laboratories Division, American Cyanamid Company, Pearl River, New York. The general description of the microorganism, based on diagnostic characteristics ob-served, is the same as that for NRRL 5647 published in United States Patent No. 3,812,249, but is reproduced below for convenience.
Observations were made of the cultural, phys-iological and morphological features of NRRL 8180 in accordance with the methods detailed by Shirling and Gottlieb, Internat. Journ. of Syst. Bacteriol., 16, 313--340 (1966). The underscored descriptive colors and color chip designations are taken from Jacobson, et al., Color Harmony Manual, 3rd Edition (1948), Container Corp.
of America, Chicago, Illinois. Descriptive details are recorded in Tables I through IV below.
Amount of Growth Good on yeast extract, Kuster's oatflake, tomato paste-oatmeal and potato-dextrose agars; moderate on aspargine-dextrose, Hickey and Tresner's, inorganic salts-starch and Bennett's agars; light on Czapek's so-lution agar.
Aerial Mycelium Whitish to yellowish, becoming grayish in sporula-tion zone~ ranging from Fawn (4 ig) to Beaver (4 li) to A~hes (5 fe). Sporulation zones becoming black and hygroscopic in older cultures.
Soluble Pigments None on most media; yellowish on yeast extract, : - .;., ~ . ~
. ~ , 1~39~
1 Bennett's and potato-dextrose agars and only in light amounts.
Reverse Color Generally in yellowish shades on most media.
5 Miscellaneou~ Physiological Reactions Nitrates reduced to nitrites; complete liquefaction of gelatin; no formation of melanoid pigments on peptone--iron agar; complete peptonization of purple milk in 7 days; tolerance of NaCl in growth medium > 7 percent but ~ 10 percent. Carbon source utilization according to the method of ~ridham and Gottlieb, J. Bacteriol., _, 107-114 (1948) as follows: Good utilization of adon-itol, d-galactose, d-fructose, d-raffinose, salicin, d-xylose and dextrose; poor or no utilization of d-melezi-tose, d-melibiose, l-arabinose, i-inositol, lactose, d-mannitol, l-rhamnose, sucrose and d-trehalose.
Micromorpholog~
Aerial mycelium gives rise to spore-bearinc branches which terminate in tightly coiled spirals of several turns; pores are mostly isodiametric, cylindrical, phalangiform, 0.6-0.7~m x 0.7-0.8,um. Spores smooth as determined by electron microscopy; ~pore sheaths finely wrinkled.
On the basis of the general characteristics observed, microorganism NRRL 8180 is a member of a large group of streptomycetes characterized by gray spores, spiral spore chains, smooth-walled spores and lack of melanin pigments. The hygroscopic nature of the culture along with its entire composite of morphological and physiological characteristics makes it a representative 39~9 strain of Streptomyces hygroscopicuc as defined by H.
D. Tresner and E. J. Backus, "A Broadened Concept of the Characteristics of Streptomyces hygroscopicus", Appl. Microbiol., 4, 243-250 (1956) and ~. D. Tresner, 5 E. J. Backus and J. A. Hayes, "Morphological Spore Types in the Streptomyces hygroscopicus-like Complex", Appl.
Microbiol., 15, 637 639 (1967).
~0 39~
U U ~, ~U
~ . _~ O ,, ~ C _~
~ ~ Vc ~ L~ Vc U~
V Ll .C U o C U C. N O
9~ C C N C C N 11) _1 C C N
Vl o '~'~ ,a C,0~5, ~ U) o u ~ ~ 8 ~ ~ u O h O _ ~
~ U ~ _ ~ ~ _ z ~ ~o 8 v N oo ,u~l ~03 ~ C lal ~
~ .. _ .
O . ~V~ ~r ~ ~ tl C 0'~ O C C . C , U~ ~ ~.rl __ _.. _.
v . ~ . 0 ~ ~:
8 ~ V ~ I ~C I I ,~ O
E~ ~ e, .~ v ~ v ~ O ~ v u ~ ~
q.l .,1 U r~ C3 ~ 'C ~ ~ 3 ul 8 o~ e E ~ ,c u~ ~ ~ v u E ,~ v ''~ 3-ek Vi ~ 3k; ul .,.~ 1 v 1~ .3 v u ~t c ~ 1~ u ~UJ ~ OD.
.~ ~ ~ ~ ~ e ~r ON ~0 e ~ ON e -~ u' vu 16 ~ o ,~ O c ~ o~e ~ ~
~a u u vl r~ o :~ ~ c r~ o ~ .~ e ~ o c ~ .
_ ~ ~o ~ ~ v o 5 u ~ o ~ ~ ~
I~J V'3 V V
V 3 C ~3 O - . ~:
:' _ ,0 .~ .. ___ ~1 ~ V~U ~ X .
C .~ .~ ~X O C
h U~ ),~ ~1 C ,a Id ~ ~ Ul ~ U~ ~ ~ ~
10~ 9~9 ~ ~ o ~ j:
xoo ~L'8 ~uo~ ~8 o 8 ~ ~ ~i e A I l 1~ 3 ~ 1~ ¦
_ ~1 8 :~ 3c ~c u o~ ~.~
v ! be St~ Zb-~ cs ~ ~a o~ 2~ 0 ~ ~ o ~ ~c` o~ ~ 5 c-V~
~ ~ o ~ ~ l ~
~ c ~ ~ ~ c~i ~ ~ i Y
- -- 9 - :
1~399~
U U
o~ Q~,, 0 h ~) .
~ r~C S~ ~
td ~1 .C C N
~ ~t: ,0 1~ ~
~ O ~ O
oE~
~ i ' 00 ~ .C`
~ ~ i) 3 ~ ~ : ~ , ~ .
.~ ~ O I
~ O ,CSI~rlO
H~ . ~ ~ ~
~1 u~ ~ 1 3 C ~r 0 nO ~ O.~ .
~a t~ ~ 1~ E~ C
E~ 0 ~ ul :~ O ~ O
O Ei~1 U ;~ N (O
~0 la ~ a) ,q ~ c~ , .~ '~ ~ ~0 'J~ EOi~
~ a~ ~ .,~ ~
3^
~ . ,1~ o.
S ~ P
~ _ :~ ~30 ~
1~
~1 ~ ,~, .~ .~ X
~ ~0 .: .~ ',; .. , ' . . . ` ': , . ~ :
,........................ 1~3g~9 ' ~2 aJ ~
~, ,, ~ ~,, .
ut ~n Q.
~ ~o - a) ~
~ s U~ s , o ~ o P. o o X X
,, .,1 3 . ~ U~ t` CO
~ ~ 00 `~
O ~
~1 ~ E3,0~E3, . ..
U~ ~ ~ ~ O , ,.
S ~1 ' H Cl ~rl-rl H U~~ E ~
~ o U~ ' ~ ~ ~ ~ ' o o_ ~ O Q ~ ~ ' .
E~ n U~-rl U Q~ . .
~ ~ ' U~~ U~ ~ ' a~ ~ ui O ~ U .~ ' ::~ t~
O ~ ~ ~ A ~I r O ,1 U~ .C ~I ~
.c _l ~ a.\ c.~ o )-I
8 ~ ,, o .~
2 :~0 U ~ ~a) ~ ~ ~ q ,~ ~ 0 ~ ' O ~ _1~ ~0 ~rl rl ~ ~ O-rl ' X~ O r~ Q
a) ~
In ~ a . . ~ . .. _ ~ .
rl ~
~ ~-~ .
~ 11 ~
- .
', . ' ' ' ' . ' ' ' ' .
o rol o u~ ,~
oo ~ o o ,~
~1 u ~ ~ ~ ~ ~
01~ (~1 U a~ N
~U
~:1 ~
--I V ~u ~ u ~ jr1 z ~ ~
~ ~ o Ul ~
:~ O~ , , n a.) V
u o 0 u~
~1 ~1 ~ o ~ ~ l U a~
o ,~ ~ 1 ,q U tq ),~
U~ ~ ~ ~ ~ U ~ UdP
s ~ a z a 8 : ~' 8 ~
~ . .
u) ~ . .
a) o u ~
~ o o o o o o .
o si o o ~ o ~ ~
~ ~ ~ .
H CJ v .
H U~ _ _ ~ O _~ . . ~ ~.
5~ U~ CO ~
E~ O ~ u~ O u~ U~ ' .~ ~ ~~ ~ ~ ~ .
~ ~:: ~ a /a .
~ rl a ~ a r~ o ~: ~ ~
U ~H .
O _ _ .
O ~ ~
Ul ~ ~Z.
.C h S~ ~ _ u~
O :~
~rl ~ ~ S U ~
~:1 ~ ~ O .Y la ~ .
.,~
_1 ~ ~ X
U U
~ ~
Ul ~ ~ ~ O
~1 ~
X' t~ ~1 ~ h /~ ' ) 1 O O ~ P~ P1 ~`' : .. , . .. :
..... : :.
3g~9 Table IV
Carbon Source Utilization Pattern of Streptomyces hygroscopicus NRRL 8180 Incubation: 10 Days Temperature: 28C
Carbon Source Utilization*
Adonitol 3 :
l-Arabinose 0 Dextran 3 d-Fructose 3 i-Ino~itol 0 Lacto~e 0 d-Mannitol 0 d-Melezitose d-Melibio~e d-Raffinose 3 l-Rhamnose O
Salicin 3 Sucrose 0 d-Trehalo~e 0 d-Xylose 3 Dextrose 3 Negative Control 0 ~3 - Good utilization 2 ~ Pair utilization 1 - Poor utilization 0 - ~o utilization .
,. . . .
1 It i5 to be understood that for the production of BL580Q, the present inventicn is not limited to this particular microorganism or to microorganisms fully ans-wering the growth and microscopic characteristics of 5 NRRL 8180. In fact, it is desired and intended to in-clude the use of mutants produced from NRRL 8180 by var-iou mean~, such as X-radiation, ultraviolet radlation, nitrogen mustard, phage exposure and the like.
Antibiotic ~L580~ is highly effective in con-trolling coccidial infections in a warm-blooded animal host. Furthermore, antibiotic BL580~ is markedly less toxic than antibiotic BL580~ (whose structure is set forth in Netherlands Patent No. 7,402,938). The activ-ity of antibiotic BL580~ as an anticoccidial agent was demonstrated by the following ln vlvo tests wherein the following poultry diet was used.
Viatamin-Amino Acid Premix 0.5~
Trace Minerals 0.1%
Sodium Chloride 0.3~
Dicalcium Phosphate 1.2%
Ground Limestone 0.5%
Stabilized Fat 4.0%
Dehydrated Alfalfa (17% protein) 2.0%
Corn Gluten Meal (41% protein) 5.0%
Menhaden Fish Meal (60~ protein) 5.0~
Soybean Oil Meal (44% protein) 30.0%
Ground Yellor Corn, fine to 100~
The vitamin-amino acid premix in the above poultry diet was prepared from the following formulation.
The expressions of quantity relate to units per kilogram 10~3999 1 of the poultry diet.
Butylated Hydroxy Toluene125 mg.
dl-Methionine 500 mg.
Vitamin A 3300 I.U.
Vitamin D3 1100 I.C.U.
Riboflavin 4.4 mg.
Vitamin E 2.2 I.U.
Niacin 27.5 mg.
Pantothenic Acid 8.8 mg.
Choline Chloride 500 mg.
Folic Acid 1.43 mg -Menadione Sodium Bisulfate 1.1 mg.
Vitamin B12 11 mcg.
Ground Yellow Corn, fine to5 gm.
Mixed Coccidia Infections of Eimeria tenella _ and Eimeria acervulina A mixed inoculum of 5000 sporulated oocysts of Eimeria acervulina and a sufficient number of oocysts of Bimeria tenella to produce 85% to 100% mortality in un-treated controls was given to groups of seven-day-old chicks, by direct in~culation into the crops of all chicks. The chicks were given free access to the poul-try diet and water during the entire test period. Two days after inoculation, medicated feed, compofied of the poultry diet and several levels of BL580~, was presented to the various groups of chicks in the test. Ten days after incoulation the tests were terminated. The chicks were weighed, necropsied and their intestinal tracts examined for lesions. The results of this test appear in Table V. Theee results show that 100~ ~urvival of $()5~3'3~9 l infected chicks was obtained when 125 ppm or 250 ppm of BL580~ was administered to infected chicks in their diet. These results also show a significatnt suppres-sion of lesions due to Eimeria tenella and Eimeria acer-vulina when 30 ppm or 60 ppm of BL580~ is administeredto infected chicks in their diet.
; ~
~3999 ¦ o ~ I o o o r I
3 0a¦ .
~ O O O ~D O
~a 1 ~r :~ _ ~I
a) ~ ~ ~o '~ r~ o o _i o E~ ~ ~ _l o o a~ ~D
P~ U~ ~ .
. .._____~
.
o~
a~ u~ o u~
~ ~a ~
m _ _ , ,o~
o .~
~ ~ O O U~ O C
~ ~ U~ ~ ~ ~
~1 ~ _1 ~ ~1 .
o~ .
10?~39~9 1 ~ixed Coccidia Infection of Eimeria tenella, Eimeria acervulina, Eimeria necatrix, Eimeria brunetti and Eimeria maxima A commercial vaccine (Coccivac~ D, Sterwin Lab-oratories, Opalika, Alabama) containing a mixture of at least five species of Eimeria coccidia, was administer-ed to chicks at 70 times the normal immunizing dose.
The vaccine was given to groups of ~even-day-old chicks, by direct inoculation into the crops of all chicks. The chicks were given free access to water and the above poultry diet during the entire test period. Two days - after inoculation medicated feed, composed of the poul-try diet and several levels of BL580~, was presented to the various groups of chicks in the test. Ten days after inoculation the tests were terminated and the birds were weighed, necrcpsied and their intestinal tracts examined for lesions. The results of this test appear in Table VI. These results show that 100% sur-vival of infected chicks is obtained when 120 ppm of BL580~ is administered to infected chicks in their diet.
This level also shows a significant suppression of les-ions due to Eimeria tenella, Eimera acervulina, Eimeria necatrix, Eimeria brunetti and Eimeria maxima.
lV~ 39S~
~1 ~ -Xl ~ ~o co .o ~. 1 o a~ o ~ 41 _1 ~
~1 a~) Xl ~-P~ ~ ~- o o o ~o '3 11~ ~ ~
L~ 1~ ~ O O ~ 1~.
a 0 o al ~1 ~ ~
~rl o o o~:
U~
_ .
o ~ .
~ ~ U~
Z ~ :
~ . ,1~ o.
S ~ P
~ _ :~ ~30 ~
1~
~1 ~ ,~, .~ .~ X
~ ~0 .: .~ ',; .. , ' . . . ` ': , . ~ :
,........................ 1~3g~9 ' ~2 aJ ~
~, ,, ~ ~,, .
ut ~n Q.
~ ~o - a) ~
~ s U~ s , o ~ o P. o o X X
,, .,1 3 . ~ U~ t` CO
~ ~ 00 `~
O ~
~1 ~ E3,0~E3, . ..
U~ ~ ~ ~ O , ,.
S ~1 ' H Cl ~rl-rl H U~~ E ~
~ o U~ ' ~ ~ ~ ~ ' o o_ ~ O Q ~ ~ ' .
E~ n U~-rl U Q~ . .
~ ~ ' U~~ U~ ~ ' a~ ~ ui O ~ U .~ ' ::~ t~
O ~ ~ ~ A ~I r O ,1 U~ .C ~I ~
.c _l ~ a.\ c.~ o )-I
8 ~ ,, o .~
2 :~0 U ~ ~a) ~ ~ ~ q ,~ ~ 0 ~ ' O ~ _1~ ~0 ~rl rl ~ ~ O-rl ' X~ O r~ Q
a) ~
In ~ a . . ~ . .. _ ~ .
rl ~
~ ~-~ .
~ 11 ~
- .
', . ' ' ' ' . ' ' ' ' .
o rol o u~ ,~
oo ~ o o ,~
~1 u ~ ~ ~ ~ ~
01~ (~1 U a~ N
~U
~:1 ~
--I V ~u ~ u ~ jr1 z ~ ~
~ ~ o Ul ~
:~ O~ , , n a.) V
u o 0 u~
~1 ~1 ~ o ~ ~ l U a~
o ,~ ~ 1 ,q U tq ),~
U~ ~ ~ ~ ~ U ~ UdP
s ~ a z a 8 : ~' 8 ~
~ . .
u) ~ . .
a) o u ~
~ o o o o o o .
o si o o ~ o ~ ~
~ ~ ~ .
H CJ v .
H U~ _ _ ~ O _~ . . ~ ~.
5~ U~ CO ~
E~ O ~ u~ O u~ U~ ' .~ ~ ~~ ~ ~ ~ .
~ ~:: ~ a /a .
~ rl a ~ a r~ o ~: ~ ~
U ~H .
O _ _ .
O ~ ~
Ul ~ ~Z.
.C h S~ ~ _ u~
O :~
~rl ~ ~ S U ~
~:1 ~ ~ O .Y la ~ .
.,~
_1 ~ ~ X
U U
~ ~
Ul ~ ~ ~ O
~1 ~
X' t~ ~1 ~ h /~ ' ) 1 O O ~ P~ P1 ~`' : .. , . .. :
..... : :.
3g~9 Table IV
Carbon Source Utilization Pattern of Streptomyces hygroscopicus NRRL 8180 Incubation: 10 Days Temperature: 28C
Carbon Source Utilization*
Adonitol 3 :
l-Arabinose 0 Dextran 3 d-Fructose 3 i-Ino~itol 0 Lacto~e 0 d-Mannitol 0 d-Melezitose d-Melibio~e d-Raffinose 3 l-Rhamnose O
Salicin 3 Sucrose 0 d-Trehalo~e 0 d-Xylose 3 Dextrose 3 Negative Control 0 ~3 - Good utilization 2 ~ Pair utilization 1 - Poor utilization 0 - ~o utilization .
,. . . .
1 It i5 to be understood that for the production of BL580Q, the present inventicn is not limited to this particular microorganism or to microorganisms fully ans-wering the growth and microscopic characteristics of 5 NRRL 8180. In fact, it is desired and intended to in-clude the use of mutants produced from NRRL 8180 by var-iou mean~, such as X-radiation, ultraviolet radlation, nitrogen mustard, phage exposure and the like.
Antibiotic ~L580~ is highly effective in con-trolling coccidial infections in a warm-blooded animal host. Furthermore, antibiotic BL580~ is markedly less toxic than antibiotic BL580~ (whose structure is set forth in Netherlands Patent No. 7,402,938). The activ-ity of antibiotic BL580~ as an anticoccidial agent was demonstrated by the following ln vlvo tests wherein the following poultry diet was used.
Viatamin-Amino Acid Premix 0.5~
Trace Minerals 0.1%
Sodium Chloride 0.3~
Dicalcium Phosphate 1.2%
Ground Limestone 0.5%
Stabilized Fat 4.0%
Dehydrated Alfalfa (17% protein) 2.0%
Corn Gluten Meal (41% protein) 5.0%
Menhaden Fish Meal (60~ protein) 5.0~
Soybean Oil Meal (44% protein) 30.0%
Ground Yellor Corn, fine to 100~
The vitamin-amino acid premix in the above poultry diet was prepared from the following formulation.
The expressions of quantity relate to units per kilogram 10~3999 1 of the poultry diet.
Butylated Hydroxy Toluene125 mg.
dl-Methionine 500 mg.
Vitamin A 3300 I.U.
Vitamin D3 1100 I.C.U.
Riboflavin 4.4 mg.
Vitamin E 2.2 I.U.
Niacin 27.5 mg.
Pantothenic Acid 8.8 mg.
Choline Chloride 500 mg.
Folic Acid 1.43 mg -Menadione Sodium Bisulfate 1.1 mg.
Vitamin B12 11 mcg.
Ground Yellow Corn, fine to5 gm.
Mixed Coccidia Infections of Eimeria tenella _ and Eimeria acervulina A mixed inoculum of 5000 sporulated oocysts of Eimeria acervulina and a sufficient number of oocysts of Bimeria tenella to produce 85% to 100% mortality in un-treated controls was given to groups of seven-day-old chicks, by direct in~culation into the crops of all chicks. The chicks were given free access to the poul-try diet and water during the entire test period. Two days after inoculation, medicated feed, compofied of the poultry diet and several levels of BL580~, was presented to the various groups of chicks in the test. Ten days after incoulation the tests were terminated. The chicks were weighed, necropsied and their intestinal tracts examined for lesions. The results of this test appear in Table V. Theee results show that 100~ ~urvival of $()5~3'3~9 l infected chicks was obtained when 125 ppm or 250 ppm of BL580~ was administered to infected chicks in their diet. These results also show a significatnt suppres-sion of lesions due to Eimeria tenella and Eimeria acer-vulina when 30 ppm or 60 ppm of BL580~ is administeredto infected chicks in their diet.
; ~
~3999 ¦ o ~ I o o o r I
3 0a¦ .
~ O O O ~D O
~a 1 ~r :~ _ ~I
a) ~ ~ ~o '~ r~ o o _i o E~ ~ ~ _l o o a~ ~D
P~ U~ ~ .
. .._____~
.
o~
a~ u~ o u~
~ ~a ~
m _ _ , ,o~
o .~
~ ~ O O U~ O C
~ ~ U~ ~ ~ ~
~1 ~ _1 ~ ~1 .
o~ .
10?~39~9 1 ~ixed Coccidia Infection of Eimeria tenella, Eimeria acervulina, Eimeria necatrix, Eimeria brunetti and Eimeria maxima A commercial vaccine (Coccivac~ D, Sterwin Lab-oratories, Opalika, Alabama) containing a mixture of at least five species of Eimeria coccidia, was administer-ed to chicks at 70 times the normal immunizing dose.
The vaccine was given to groups of ~even-day-old chicks, by direct inoculation into the crops of all chicks. The chicks were given free access to water and the above poultry diet during the entire test period. Two days - after inoculation medicated feed, composed of the poul-try diet and several levels of BL580~, was presented to the various groups of chicks in the test. Ten days after inoculation the tests were terminated and the birds were weighed, necrcpsied and their intestinal tracts examined for lesions. The results of this test appear in Table VI. These results show that 100% sur-vival of infected chicks is obtained when 120 ppm of BL580~ is administered to infected chicks in their diet.
This level also shows a significant suppression of les-ions due to Eimeria tenella, Eimera acervulina, Eimeria necatrix, Eimeria brunetti and Eimeria maxima.
lV~ 39S~
~1 ~ -Xl ~ ~o co .o ~. 1 o a~ o ~ 41 _1 ~
~1 a~) Xl ~-P~ ~ ~- o o o ~o '3 11~ ~ ~
L~ 1~ ~ O O ~ 1~.
a 0 o al ~1 ~ ~
~rl o o o~:
U~
_ .
o ~ .
~ ~ U~
Z ~ :
4~ .
OQ.
o ~
~ o o o o h 1: ~ ~ ~
~ _1 ~:
1 Fermentation Process , Cultivation of the microorganism Streptomyces hygroscopicus NRRL 8180 may be carried out in a wide variety of liquid culture media. Media which are useful for the production of antibiotic BL580~ include an assim-ilable source of carbon such as starch, sugar, molasses, glycerol, etc.; an assimilable source of nitrogen such as protein, pro~ein hydrolysate, polypeptides, amino acids, corn steep liquor, etc.; and inorganic anions and cations such as potassium, sodium, calcium, sulfate, phosphate, chloride, etc. Trace elements such as born, molybdenum, copper, etc. are supplied as impurities of other constituents of the media. Aeration in tanks and bottles is provided by forcing sterile air through or onto the surface of the fermenting medium. Further agi-tation in tanks i8 provided by a mechanical impeller.
An antifoaming agent such as one percent octadecanol in lard oil may ~e added as needed.
Inoculum Pre~aration Shaker flask inoculum of Streptomyces hygro-scopicus NRRL 8180 is prepared by inoculating 100 ml.
portions of sterile liquid in 500 ml. flasks with scrap-ings or washings of spores from an agar slant of the culture. The following medium is ordinarily used:
Soy flour 1.0%
Glucose 2.0%
Corn steep liquor 0.5%
CaCO3 0.3%
Water qs 100%
The flasks are incubated at a temperature from :, ~
10~3999 1 25C. to 29C., preferably 28C. and agitated vigorou~ly on a rotary shaker for 48 to 96 hours.
Two 100 ml. portion~ of this inoculum are used to inoculate 12 liter~ of the same sterile medium in a 20 liter bottle. This inoculum i8 incubated with agita-tion and aeration of sterile air for 36 to 64 hours at 25C. to 29C., preferably 28C.
This inoculum is used to inoculate 30~ liters of the same sterile medium in a tank fermentor. This inoculum is incubated with agitation and aeration of ~terile air for 36 to 64 hours at 25C. to 29C., pref-erably 28C.
This inoculum is used to inoculate a 40~0 liter fermentation tank containing 3000 liters of a sterile medium such as the following:
Corn steep liquor 0.5%
Soy flour 1.0%
Corn starch 4.0 CaC~3 0.1~
Water qs 100%
This medium i5 fermented for 100 to 200 hours at a temperature of 27C. to 32C. with agitation by an impeller and aeration at a rate of 0.4-0.8 liter~ of air per liter of medium per minute. Normally a defoamer such as Hoda~ FD82 i~ added at a ratio of about 1.3 gal./1000 gal. of medium.
Purification Procedure , .
After the fermentatioTI i8 completed, the fer-mented ma~h containing antibiotic ~L580~ i~ combined with about one-half it~ volume of ethyl acetate and stirred Registered Trademark B
~0~3999 1 for 2-3 hours. An approximate 8% portiOn of diatomace-OU5 earth is added and the mixture is filtered through a plate and frame filter pres3. The cake is washed on the press with ethyl acetate. The ethyl acetate ex-tract~ are collected and concentrated in a still toa syrup.
The above syrup is stirred with twice its vol-ume of heptane and stored at 4C. overnight. The super-natant is recovered by decantation and concentrated to a gummy residue.
The gummy concentrate is treated with 10 liters of methanol and chilled with the aid of dry ice for sev-eral hours. The mixture is filtered through sintered glass with diatomaceous earth precoat and washed with cold methanol. The methanol solution is concentrated to dryness ln vacuo.
A chromatographic column is prepared with ac-, tivated carbon at a ratio of about one liter of carbon per 50 g. of charge. The dried residue is dissolved in methylene chloride at a ratio of 40 g./liter and chargedon the column. The methylene chloride eluate is collec-' ted as one cut and concentrated to dryness. The residue is mixed with methanol and stored in a chill room with dry ice to reduce the temperature to -10C. for 15 min-, 25 utes. After 15 minute9 the solidified oil is filtered off and the methanol soluble material is concentrated to I dryness in vacuo giving an oil.
:. _ Thi~ oil is dissolved in a minimum aount of methylene chloride, combined with ~ilica gel, concentrat-ed to dryness and charged on a dry silica gel column.
:~
- 2~ -.. . .
, ~
1 The column i8 developed with 10% ethyl acetate in ben-zene followed by 20% ethyl acetate in benzene. The column is then allowed to drain. The column is meas-ured into 10 equal parts (including the charge). Core samples are removed at Rf 0.05, 0.15, 0.25, 0.35 ...etc., for the length of the entire column and eluted with an appropriate volumn of ethyl acetate:methylene chloride:-methanol (2:2:1). At places where the antibiotic over-lap~, core samp1ing is done at every 1/8 of an Rf unit.
The antibiotic is located by thin layer chromatography of the core elutates on commercially available thin lay-er plates (Silplate-22*distributed by Brinkmann Instru-ment Co., Westbury, New York 11590). The respective zones were detected by charring in the presence of sul-furic acid.
The section of the column comprising Rf 0.11to 0.35 is excised from the column and slurried in ethyl acetate:methylene chloride:methanol (2:2:1 by volume~.
This mixture is filtered, washed with additional solvent mixture and concentrated ln vacuo to dryness. The resi-due is dissolved in t-butanol, filtered and freeze dried to give a ~luffy solid.
A two-phase system is prepared by mixing n-heptane:methanol:ethyl acetate:water (3000:1500:75:37 by volume). Celato~ (Eagle-Picher Industries, Cincinnati, Ohio), a brand of dia~omaceous earth, is mixed with the lower phase of this system at a ratio of about 800 g./600 ml. of lower phase and packed in increments into a (7.5 cm. in diameter) column. The charge is applied as a mixture of diatomaceous earth, lower phase and lyophil-Registered Trademark 3~3~9 1 lized product (40 g.:30 ml.:13.8 g.). The charged col-umn is d~veloped with upper phase and fractions of 25 ml.
are collected. The activity is detected by thin layer chromatography on selected fractions using a gelplate, chloroform:ethyl acetate (1:1) as developer and charring for detection. Fractions 90-150 are combined and con-centrated giving antibiotic BL580~/
The invention will be described in greater de-til in conjunction with the following specific examples.
Example 1 Inoculum Preparation A typical medium used to grow the primary in-oculum is prepared according to the following formula:
Soy flour 1.0 g.
15 Glucose 2.0 g.
Corn ~teep liquor 0.5 g.
CaCO3 0.3 g.
Water to 100 ml.
The washed or scraped spores from an agar alant of Stre~_ myces hygroscopicus NRRL 8180 are used to inoculate two 500 ml. flasks each containing 100 ml.
of the above medium which has been sterilized. The flasks are placed on a rotary shaker and agitated vig-orously for 72 hours at 28C.
The resulting flask inoculum is transferred to a 5 gallon glass bottle containing 12 liters of the same sterile medium. This secondary inoculum is aerated with sterile air while growth is carried out for 48 hours at 28C.
~ 30 The resulting secondary inoculum is transferred ; - 24 -:
i()~39~
1 to a 100 gallon tank containing 300 liters of the same sterile medium. This tertiary in~culum is aerated with sterile air at the rate of one liter of air/liter of med-ium/minute and agitated by an impeller operating at 173 rpm. Growth is continued for 48 hours at 28C. The pH
at this time is 6.9 to 7Ø
Example 2 Fermentation A fermentation medium i8 prepared according to the following formula:
Corn steep liquor o.s g.
Soy flour 1.0 g.
Corn starch 4.0 g.
CaCO3 0.1 g.
Water to 100 ml.
A 3000 liter batch of fermentation medium of the above formulation in a 4000 liter tank is ~terilized at 120C. for 60 m~nutes. The pH of the medium after sterilization is 6.4 to 6.5. This medium is inoculated with 300 liters of tertiary inoculum prepared as describ-ed in Example 1. The fermentation is carried out at 28--30C., using 4.0 liters of Hodag FD82 as a defoaming agent. Aeration is supplied at the rate of 0.6 liter of sterile air per liter of mash per minute. The mash is agitated by an impeller driven at 150 rpm. At the end of 138.5 hours of fermentation time the mash i9 harvested.
Example 3 Iqolation and Purification A 2550 liter portion of fermented mash prepared as described in Example 2, having a pH of 7.4 i~ combined ':
-, .~, 1~3~9 1 with 1275 liters of ethyl acetate and stirred for 2.5 hour~. An 8~ (by weight) portion of diatomaceou~ earth i8 added. The mixture is filtered in several portions, with stirring, through a pair of frame presses. The aqueous-ethyl acetate filtrates are pooled providing 3250 liters which is allowed to separate, providing 1000 liters of ethyl acetate extract. After each portion of mash-ethyl acetate-diatomaceous earth is filtered through a press, the pad is washed on the press with ethyl ace-tate. The ethyl acetate wa3hings are combined and sep-arated giving 535 liters of ethyl acetate washings. The 1000 liters of ethyl acetate extracts and 535 liters of ethyl acetate washings are combined and concentrated in a 400 gallon still to 225 liters. This 225 liters is further concentrated in a 50 gallon still to 20 liters.
This 20 liters is further concentrated in a glass still to a syrup.
The syrup iB stored at 4C. for 48 hours and then stirred with twice its volume of heptane. The mix-ture is allowed to stand at 4c. overnight. The super-natant i8 recovered by decantation and concentrated to a gummy residue.
A 10 liter portion of methanol is added to the gummy residue and the mixture is chilled with the aid of dry ice for several hours. The mixture is filtered through sintered glass containing a diatomaceous earth precoat and washed with cold methanol. The combined filtrate and washings are concentrated to dryness ln vacuo providing 1353.5 g. of residue.
-The 1353.5 g. of residue is dissolved in meth-1 ylene chloride at a rate of 40 g./liter. A chromato-graphic column is prepared by packing with 27.07 liters of 20 x 40 mesh granular carbon. The residue in meth-ylene chl~ride is passed through this column at a flow rate of 375-400 ml. per minute. The methylene chloride eluate is collected as one cut and concentrated to dry-ness giving 1053 g. of residue. The residue is thor-ou~hly mixed with 8-9 liters of methanol. The mixture i~ reduced to -10C. in a chill room with the aid of dry ice and maintained at -10C. for 15 minutes. Any solid-ified oil is removed by filtration and the methanol fil-trate is concentrated to dryness in vacuo giving 781.4 g. as an oil.
A dry pack chromatographic column is prepared by packing 4 kg. of silica gel onto a 12" circumference plastic column. A 200 g. portion of the above oil is dissolved in a minimal amount of methylene chloride. A
;I 300 g. portion of silica gel is added and mixed thoroughly and the mixture is then concentrated in vacuo to dryness.
The dried mixture is charged on the column and some sea sand is placed on the top of the column to prevent bed disturbance during elution. The plastic column is placed in a glass shell to give it support. The column is eluted with 12 liters of 10~ ethyl acetate in benzene.
The column is allowed to run dry and then eluted with 7.6 liter~ of 20% ethyl acetate in benzene. Cuts are collect-ed and the column is allowed to run dry. The column is then purged with nitrogen. Antibiotic activity is de-termined by assaying the cuts vs. Streptococcus pyogenes NY5. The column is measued into 10 equal parts (includ-. .
., . .:
~0~3~9~
1 ing the charge). Core samples are removed at Rf 0.05, 0.15, 0.25, 0.35..... etc., for the length of the entire column. At places where the antibiotic bands overlapped, core sampling is done at every 1/8 of an Rf unit. Each core,sample is eluted with 10 ml. of ethyl acetate:meth-ylene chloride:methanol (2:2:1) and examined by thin layer chromatography using the system ethyl acetate:-chloroform (1:1) spotting 30 of sample and charring with sulfuric acid. The section of column Rf 0.11 to Rf 0.35 is removed and slurried in ethyl acetate:methylene chloride:methanol (2:2:1). The mixture is filtered and washed with the same solvent mixture and concentrated to dryness ln vacuo. The residue is dissolved in t--butanol, filtered and lyophilized giving 26.7 g.
A two-phase system i5 prepared by mixing n-heptane:methanol:ethyl acetate:water [3000:1500:75:37 ; (by volume)]. An 800 g. portion of acid washed diato-maceous earth is mixed with 600 ml. of the lower phase of this solvent sy~tem and packed in increments into a 7.5 cubic inch gla~s column. The charge, comprising 40 g. of diatomaceous earth, 30 ml. of lower phase solvent and 13.8 g. of the above lyophilized material, is applied as a mixture. The charged column is developed with the upper phase of the solvent system and 25 ml. fractions are collected. The desired compound is located by assaving fraction samples as above with thin layer chromatography. Fractions 90-150 are combined and lyophilized providing 2.75 g. of the product BL580~ pri-marily as the sodium salt.
1 Example _ Preparation and Isolation of BL580~ as the Free Acid The partial sodium salt of BL580~ is prepared and isolated as described in Exampels 1-3. A two-phase system is prepared by mixing heptane, methanol, ethyl acetate, water (3000:1500:80:40 by volume). A glass column is packed with a mixture of 800 g. of diatomace-ous earth and 600 ml. of the lower phase of the above system. The charge is applied as a mixture of 28 g. of diatomaceous earth, 21 ml. of lower pha~e and 10.9 g.
of the BL580Q partial sodium salt. The column is de-veloped with upper phase. Fractions of 90 ml. volume are collected. Selected fractions are chromatographed on Silplate~ F-22 using ethyl acetate:chloroform as de-veloper and charring for detection in order to locatethe BL580~. Fractions 29-39, containing the BL580~
are combined and the solvent is removed. The resulting solid i8 redissolved in t-butanol and lyophilized giv-ing 4.79 g-An 800 mg. portion of this lyophilized mater-ial is stirred in 300 ml. of a two-phase system composed of water:ether:petroleum ether (2:1:1). The pH is ad-justed to 2.5 using lN HC1 while stirring. The organic phase is separated and washed three times with an equal volume of water. The solvent extract is concentrated in vacuo to a residue. The residue is dissolved in t--butanol and then lyophilized giving 657 mg. of BL580 as the free acid.
~he free acid of BL580~ has microanalytical data as follows: C, 61.10; H, 8.9; ash, 0; and a spe-;. . :. : .......... .
10~3999 l cific rotation l~]25 = +21 + 1 (C=0.9 in methanol).
The free acid of BL580~ exhibited character-istic absorption in the infrared region of the spectrum at the following wavelengths: 2.95; 5.88; 8.35; 8.60;
9.00; 9.12; 9.43; 9.62; 10.05; and 10.47~.
A standard infrared absorption spectrum of the free acid of BL580~ prepared in a KBr pellet is shown in Figure 4 of the accompanying drawings.
A standard proton magnetic resonance spectrum of the free acid of BL580~ is shown in Figure 5 of the accompanying drawings.
A standard C nuclear magnetic resonance spectrum of the free acid of BL580~ is shown in Figure 6-of the accompanying drawings.
; 15 Example 5 Preparation of the Sodium Salt of BL580~
BL580~ free acid (1 g.) is dissolved in 300 ml.
of ether~petroleum ether ~1:1). This solution is added to 200 ml. of water to give a two-phase system. The pH
is adjusted to 10.0 by the addition of 0.1N NaOH while stirring, after which the organic phaee is separated and concentrated in vacuo to a residue~ The residue is dis-solved in 10 ml. of ether and 20 ml. of petroleum ether (30-70C.) is added. The resulting solution is seeded with a crystal of BL580~ sodium salt and allowed to evap-orate slowly at 4C. until a crystalline solid forms.
The crystals are collected on a filter, washed with cold petroleum ether and air dried to yield 323 mg. of the sodium salt of BL580~.
; 30 This sodium salt of antibiotic BL580~ has a :.
. . .
1~3999 1 melting point of 157-161C.; C, 60.99; H, 8.47; Na, 1.95: [a]25 = +6 + 1 (C=1.153 in methanol). The sod-ium salt of BL580Q exhibited characteristic absorption in the infrared region of the spectrum at the following wavelengths: 6.27, 7.28, 9.0, 9.13, 9.23, 9.48 and 10.60,u.
A standard infrared absorption spectrum of the sodium salt of BL580~ prepared in a KBr pellet i8 shown in Figure 1 of the accompanying drawings.
A standard 13C nuclear magnetic resonance spectrum of the sodium salt of BL580~ is shown in Figure 2 of the accompanying drawings.
A standard proton magnetic resonance spectrum of the sodium salt of BL580~ is shown in Figure 3 of the accompanying drawings.
Example 6 Preparation and Isolation of the ~-Bromophenacyl Ester of BL580Q _ _ The partial sodium salt of BL580~ is prepared and isolated as described in Examples 1-3. A one gram portion of this BL580~ sodium salt, 834 mg. of p-bromo-phenacyl bromide, 600 mg. of lithium carbonate and 20 ml.
o dry dimethylformamide are placed in a flask and allow-ed to react at 37C. for 16 hours. Four volumes of chloroform are added and the resulting suspension is filtered. The filtrate is concentrated in vacuo to remove the ~olvent giving a syrupy re~idue. A diatomaceous earth partition column is prepared using a system com-posed of heptane:ethyl acetate:methanol:water (2000:25:-1000:17). A 120 g. portion of diatomaceous earth and 90 ..
`` 1(3S~3999 1 ml, of lower phase are used for the column. The syr-upy residue, 12 g. of diatomaceous earth and 9 ml. of lower phase are applied to the top of the column. The column is developed with upper phase. Fractions of 10 ml. each are collected. The activity in the fractions is located by thin layer chromatography. Fractions 22-41 are combined and concentrated in vacuo to a residue. The residue is dissolved in 50 ml. of methanol and filtered.
Thç filtrate is warmed on a steam bath, 10 ml. of water is added and the mixture is allowed to cool slowly to 4C.
The resulting crystals are collected giving 566 mg. of ., BL580Q as the p-bromophenacyl ester.
The ~-bromophenacyl ester of BL580~ has micro-analytical data as follows: C, 58.80; H, 7.~0; Br, 8.64;
a specific rotation [~]25 = +63 + 2 (CHC13 at 0.51%).
The ~-bromophenacyl ester of BL580~ exhibited characteristic absorption in the infrared region of the spectrum at the following wavelengths: 2.95; 5.88; 6.30;
8.20; 8.45; 8.60; 9.00; 9.15 (braod); 9.37 (broad); 9.62;
10.06; and 10.37.
The molecular weight of the ~-bromophenacyl ester of BL580~ monohydrate is 1114 + 0.3% as determined by X-ray diffraction.
A standard infrared absorption spectrum of the ~-bromophenacyl ester of BL580~ prepared in a KBr pellet is shown in Figure 7 of the accompanying drawings.
A standard ultraviolet absorption spectrum of the ~-bromophenacyl ester of BL580~ prepared at a concentration of 33.84 mcg./ml. in methanol is shown in Figure 8 of the accompanying drawings.
:. . .
1 A standard proton magnetic resonance spectrum of the p-bromophenacyl ester of BL580~ is shown in Fig-ure 9 ~f the accompanying drawings.
'~ :
! ~
,: ;
;J
P~ 30 ,':
,: , ,~, . . .
. , . , ~ ... ;: :
OQ.
o ~
~ o o o o h 1: ~ ~ ~
~ _1 ~:
1 Fermentation Process , Cultivation of the microorganism Streptomyces hygroscopicus NRRL 8180 may be carried out in a wide variety of liquid culture media. Media which are useful for the production of antibiotic BL580~ include an assim-ilable source of carbon such as starch, sugar, molasses, glycerol, etc.; an assimilable source of nitrogen such as protein, pro~ein hydrolysate, polypeptides, amino acids, corn steep liquor, etc.; and inorganic anions and cations such as potassium, sodium, calcium, sulfate, phosphate, chloride, etc. Trace elements such as born, molybdenum, copper, etc. are supplied as impurities of other constituents of the media. Aeration in tanks and bottles is provided by forcing sterile air through or onto the surface of the fermenting medium. Further agi-tation in tanks i8 provided by a mechanical impeller.
An antifoaming agent such as one percent octadecanol in lard oil may ~e added as needed.
Inoculum Pre~aration Shaker flask inoculum of Streptomyces hygro-scopicus NRRL 8180 is prepared by inoculating 100 ml.
portions of sterile liquid in 500 ml. flasks with scrap-ings or washings of spores from an agar slant of the culture. The following medium is ordinarily used:
Soy flour 1.0%
Glucose 2.0%
Corn steep liquor 0.5%
CaCO3 0.3%
Water qs 100%
The flasks are incubated at a temperature from :, ~
10~3999 1 25C. to 29C., preferably 28C. and agitated vigorou~ly on a rotary shaker for 48 to 96 hours.
Two 100 ml. portion~ of this inoculum are used to inoculate 12 liter~ of the same sterile medium in a 20 liter bottle. This inoculum i8 incubated with agita-tion and aeration of sterile air for 36 to 64 hours at 25C. to 29C., preferably 28C.
This inoculum is used to inoculate 30~ liters of the same sterile medium in a tank fermentor. This inoculum is incubated with agitation and aeration of ~terile air for 36 to 64 hours at 25C. to 29C., pref-erably 28C.
This inoculum is used to inoculate a 40~0 liter fermentation tank containing 3000 liters of a sterile medium such as the following:
Corn steep liquor 0.5%
Soy flour 1.0%
Corn starch 4.0 CaC~3 0.1~
Water qs 100%
This medium i5 fermented for 100 to 200 hours at a temperature of 27C. to 32C. with agitation by an impeller and aeration at a rate of 0.4-0.8 liter~ of air per liter of medium per minute. Normally a defoamer such as Hoda~ FD82 i~ added at a ratio of about 1.3 gal./1000 gal. of medium.
Purification Procedure , .
After the fermentatioTI i8 completed, the fer-mented ma~h containing antibiotic ~L580~ i~ combined with about one-half it~ volume of ethyl acetate and stirred Registered Trademark B
~0~3999 1 for 2-3 hours. An approximate 8% portiOn of diatomace-OU5 earth is added and the mixture is filtered through a plate and frame filter pres3. The cake is washed on the press with ethyl acetate. The ethyl acetate ex-tract~ are collected and concentrated in a still toa syrup.
The above syrup is stirred with twice its vol-ume of heptane and stored at 4C. overnight. The super-natant is recovered by decantation and concentrated to a gummy residue.
The gummy concentrate is treated with 10 liters of methanol and chilled with the aid of dry ice for sev-eral hours. The mixture is filtered through sintered glass with diatomaceous earth precoat and washed with cold methanol. The methanol solution is concentrated to dryness ln vacuo.
A chromatographic column is prepared with ac-, tivated carbon at a ratio of about one liter of carbon per 50 g. of charge. The dried residue is dissolved in methylene chloride at a ratio of 40 g./liter and chargedon the column. The methylene chloride eluate is collec-' ted as one cut and concentrated to dryness. The residue is mixed with methanol and stored in a chill room with dry ice to reduce the temperature to -10C. for 15 min-, 25 utes. After 15 minute9 the solidified oil is filtered off and the methanol soluble material is concentrated to I dryness in vacuo giving an oil.
:. _ Thi~ oil is dissolved in a minimum aount of methylene chloride, combined with ~ilica gel, concentrat-ed to dryness and charged on a dry silica gel column.
:~
- 2~ -.. . .
, ~
1 The column i8 developed with 10% ethyl acetate in ben-zene followed by 20% ethyl acetate in benzene. The column is then allowed to drain. The column is meas-ured into 10 equal parts (including the charge). Core samples are removed at Rf 0.05, 0.15, 0.25, 0.35 ...etc., for the length of the entire column and eluted with an appropriate volumn of ethyl acetate:methylene chloride:-methanol (2:2:1). At places where the antibiotic over-lap~, core samp1ing is done at every 1/8 of an Rf unit.
The antibiotic is located by thin layer chromatography of the core elutates on commercially available thin lay-er plates (Silplate-22*distributed by Brinkmann Instru-ment Co., Westbury, New York 11590). The respective zones were detected by charring in the presence of sul-furic acid.
The section of the column comprising Rf 0.11to 0.35 is excised from the column and slurried in ethyl acetate:methylene chloride:methanol (2:2:1 by volume~.
This mixture is filtered, washed with additional solvent mixture and concentrated ln vacuo to dryness. The resi-due is dissolved in t-butanol, filtered and freeze dried to give a ~luffy solid.
A two-phase system is prepared by mixing n-heptane:methanol:ethyl acetate:water (3000:1500:75:37 by volume). Celato~ (Eagle-Picher Industries, Cincinnati, Ohio), a brand of dia~omaceous earth, is mixed with the lower phase of this system at a ratio of about 800 g./600 ml. of lower phase and packed in increments into a (7.5 cm. in diameter) column. The charge is applied as a mixture of diatomaceous earth, lower phase and lyophil-Registered Trademark 3~3~9 1 lized product (40 g.:30 ml.:13.8 g.). The charged col-umn is d~veloped with upper phase and fractions of 25 ml.
are collected. The activity is detected by thin layer chromatography on selected fractions using a gelplate, chloroform:ethyl acetate (1:1) as developer and charring for detection. Fractions 90-150 are combined and con-centrated giving antibiotic BL580~/
The invention will be described in greater de-til in conjunction with the following specific examples.
Example 1 Inoculum Preparation A typical medium used to grow the primary in-oculum is prepared according to the following formula:
Soy flour 1.0 g.
15 Glucose 2.0 g.
Corn ~teep liquor 0.5 g.
CaCO3 0.3 g.
Water to 100 ml.
The washed or scraped spores from an agar alant of Stre~_ myces hygroscopicus NRRL 8180 are used to inoculate two 500 ml. flasks each containing 100 ml.
of the above medium which has been sterilized. The flasks are placed on a rotary shaker and agitated vig-orously for 72 hours at 28C.
The resulting flask inoculum is transferred to a 5 gallon glass bottle containing 12 liters of the same sterile medium. This secondary inoculum is aerated with sterile air while growth is carried out for 48 hours at 28C.
~ 30 The resulting secondary inoculum is transferred ; - 24 -:
i()~39~
1 to a 100 gallon tank containing 300 liters of the same sterile medium. This tertiary in~culum is aerated with sterile air at the rate of one liter of air/liter of med-ium/minute and agitated by an impeller operating at 173 rpm. Growth is continued for 48 hours at 28C. The pH
at this time is 6.9 to 7Ø
Example 2 Fermentation A fermentation medium i8 prepared according to the following formula:
Corn steep liquor o.s g.
Soy flour 1.0 g.
Corn starch 4.0 g.
CaCO3 0.1 g.
Water to 100 ml.
A 3000 liter batch of fermentation medium of the above formulation in a 4000 liter tank is ~terilized at 120C. for 60 m~nutes. The pH of the medium after sterilization is 6.4 to 6.5. This medium is inoculated with 300 liters of tertiary inoculum prepared as describ-ed in Example 1. The fermentation is carried out at 28--30C., using 4.0 liters of Hodag FD82 as a defoaming agent. Aeration is supplied at the rate of 0.6 liter of sterile air per liter of mash per minute. The mash is agitated by an impeller driven at 150 rpm. At the end of 138.5 hours of fermentation time the mash i9 harvested.
Example 3 Iqolation and Purification A 2550 liter portion of fermented mash prepared as described in Example 2, having a pH of 7.4 i~ combined ':
-, .~, 1~3~9 1 with 1275 liters of ethyl acetate and stirred for 2.5 hour~. An 8~ (by weight) portion of diatomaceou~ earth i8 added. The mixture is filtered in several portions, with stirring, through a pair of frame presses. The aqueous-ethyl acetate filtrates are pooled providing 3250 liters which is allowed to separate, providing 1000 liters of ethyl acetate extract. After each portion of mash-ethyl acetate-diatomaceous earth is filtered through a press, the pad is washed on the press with ethyl ace-tate. The ethyl acetate wa3hings are combined and sep-arated giving 535 liters of ethyl acetate washings. The 1000 liters of ethyl acetate extracts and 535 liters of ethyl acetate washings are combined and concentrated in a 400 gallon still to 225 liters. This 225 liters is further concentrated in a 50 gallon still to 20 liters.
This 20 liters is further concentrated in a glass still to a syrup.
The syrup iB stored at 4C. for 48 hours and then stirred with twice its volume of heptane. The mix-ture is allowed to stand at 4c. overnight. The super-natant i8 recovered by decantation and concentrated to a gummy residue.
A 10 liter portion of methanol is added to the gummy residue and the mixture is chilled with the aid of dry ice for several hours. The mixture is filtered through sintered glass containing a diatomaceous earth precoat and washed with cold methanol. The combined filtrate and washings are concentrated to dryness ln vacuo providing 1353.5 g. of residue.
-The 1353.5 g. of residue is dissolved in meth-1 ylene chloride at a rate of 40 g./liter. A chromato-graphic column is prepared by packing with 27.07 liters of 20 x 40 mesh granular carbon. The residue in meth-ylene chl~ride is passed through this column at a flow rate of 375-400 ml. per minute. The methylene chloride eluate is collected as one cut and concentrated to dry-ness giving 1053 g. of residue. The residue is thor-ou~hly mixed with 8-9 liters of methanol. The mixture i~ reduced to -10C. in a chill room with the aid of dry ice and maintained at -10C. for 15 minutes. Any solid-ified oil is removed by filtration and the methanol fil-trate is concentrated to dryness in vacuo giving 781.4 g. as an oil.
A dry pack chromatographic column is prepared by packing 4 kg. of silica gel onto a 12" circumference plastic column. A 200 g. portion of the above oil is dissolved in a minimal amount of methylene chloride. A
;I 300 g. portion of silica gel is added and mixed thoroughly and the mixture is then concentrated in vacuo to dryness.
The dried mixture is charged on the column and some sea sand is placed on the top of the column to prevent bed disturbance during elution. The plastic column is placed in a glass shell to give it support. The column is eluted with 12 liters of 10~ ethyl acetate in benzene.
The column is allowed to run dry and then eluted with 7.6 liter~ of 20% ethyl acetate in benzene. Cuts are collect-ed and the column is allowed to run dry. The column is then purged with nitrogen. Antibiotic activity is de-termined by assaying the cuts vs. Streptococcus pyogenes NY5. The column is measued into 10 equal parts (includ-. .
., . .:
~0~3~9~
1 ing the charge). Core samples are removed at Rf 0.05, 0.15, 0.25, 0.35..... etc., for the length of the entire column. At places where the antibiotic bands overlapped, core sampling is done at every 1/8 of an Rf unit. Each core,sample is eluted with 10 ml. of ethyl acetate:meth-ylene chloride:methanol (2:2:1) and examined by thin layer chromatography using the system ethyl acetate:-chloroform (1:1) spotting 30 of sample and charring with sulfuric acid. The section of column Rf 0.11 to Rf 0.35 is removed and slurried in ethyl acetate:methylene chloride:methanol (2:2:1). The mixture is filtered and washed with the same solvent mixture and concentrated to dryness ln vacuo. The residue is dissolved in t--butanol, filtered and lyophilized giving 26.7 g.
A two-phase system i5 prepared by mixing n-heptane:methanol:ethyl acetate:water [3000:1500:75:37 ; (by volume)]. An 800 g. portion of acid washed diato-maceous earth is mixed with 600 ml. of the lower phase of this solvent sy~tem and packed in increments into a 7.5 cubic inch gla~s column. The charge, comprising 40 g. of diatomaceous earth, 30 ml. of lower phase solvent and 13.8 g. of the above lyophilized material, is applied as a mixture. The charged column is developed with the upper phase of the solvent system and 25 ml. fractions are collected. The desired compound is located by assaving fraction samples as above with thin layer chromatography. Fractions 90-150 are combined and lyophilized providing 2.75 g. of the product BL580~ pri-marily as the sodium salt.
1 Example _ Preparation and Isolation of BL580~ as the Free Acid The partial sodium salt of BL580~ is prepared and isolated as described in Exampels 1-3. A two-phase system is prepared by mixing heptane, methanol, ethyl acetate, water (3000:1500:80:40 by volume). A glass column is packed with a mixture of 800 g. of diatomace-ous earth and 600 ml. of the lower phase of the above system. The charge is applied as a mixture of 28 g. of diatomaceous earth, 21 ml. of lower pha~e and 10.9 g.
of the BL580Q partial sodium salt. The column is de-veloped with upper phase. Fractions of 90 ml. volume are collected. Selected fractions are chromatographed on Silplate~ F-22 using ethyl acetate:chloroform as de-veloper and charring for detection in order to locatethe BL580~. Fractions 29-39, containing the BL580~
are combined and the solvent is removed. The resulting solid i8 redissolved in t-butanol and lyophilized giv-ing 4.79 g-An 800 mg. portion of this lyophilized mater-ial is stirred in 300 ml. of a two-phase system composed of water:ether:petroleum ether (2:1:1). The pH is ad-justed to 2.5 using lN HC1 while stirring. The organic phase is separated and washed three times with an equal volume of water. The solvent extract is concentrated in vacuo to a residue. The residue is dissolved in t--butanol and then lyophilized giving 657 mg. of BL580 as the free acid.
~he free acid of BL580~ has microanalytical data as follows: C, 61.10; H, 8.9; ash, 0; and a spe-;. . :. : .......... .
10~3999 l cific rotation l~]25 = +21 + 1 (C=0.9 in methanol).
The free acid of BL580~ exhibited character-istic absorption in the infrared region of the spectrum at the following wavelengths: 2.95; 5.88; 8.35; 8.60;
9.00; 9.12; 9.43; 9.62; 10.05; and 10.47~.
A standard infrared absorption spectrum of the free acid of BL580~ prepared in a KBr pellet is shown in Figure 4 of the accompanying drawings.
A standard proton magnetic resonance spectrum of the free acid of BL580~ is shown in Figure 5 of the accompanying drawings.
A standard C nuclear magnetic resonance spectrum of the free acid of BL580~ is shown in Figure 6-of the accompanying drawings.
; 15 Example 5 Preparation of the Sodium Salt of BL580~
BL580~ free acid (1 g.) is dissolved in 300 ml.
of ether~petroleum ether ~1:1). This solution is added to 200 ml. of water to give a two-phase system. The pH
is adjusted to 10.0 by the addition of 0.1N NaOH while stirring, after which the organic phaee is separated and concentrated in vacuo to a residue~ The residue is dis-solved in 10 ml. of ether and 20 ml. of petroleum ether (30-70C.) is added. The resulting solution is seeded with a crystal of BL580~ sodium salt and allowed to evap-orate slowly at 4C. until a crystalline solid forms.
The crystals are collected on a filter, washed with cold petroleum ether and air dried to yield 323 mg. of the sodium salt of BL580~.
; 30 This sodium salt of antibiotic BL580~ has a :.
. . .
1~3999 1 melting point of 157-161C.; C, 60.99; H, 8.47; Na, 1.95: [a]25 = +6 + 1 (C=1.153 in methanol). The sod-ium salt of BL580Q exhibited characteristic absorption in the infrared region of the spectrum at the following wavelengths: 6.27, 7.28, 9.0, 9.13, 9.23, 9.48 and 10.60,u.
A standard infrared absorption spectrum of the sodium salt of BL580~ prepared in a KBr pellet i8 shown in Figure 1 of the accompanying drawings.
A standard 13C nuclear magnetic resonance spectrum of the sodium salt of BL580~ is shown in Figure 2 of the accompanying drawings.
A standard proton magnetic resonance spectrum of the sodium salt of BL580~ is shown in Figure 3 of the accompanying drawings.
Example 6 Preparation and Isolation of the ~-Bromophenacyl Ester of BL580Q _ _ The partial sodium salt of BL580~ is prepared and isolated as described in Examples 1-3. A one gram portion of this BL580~ sodium salt, 834 mg. of p-bromo-phenacyl bromide, 600 mg. of lithium carbonate and 20 ml.
o dry dimethylformamide are placed in a flask and allow-ed to react at 37C. for 16 hours. Four volumes of chloroform are added and the resulting suspension is filtered. The filtrate is concentrated in vacuo to remove the ~olvent giving a syrupy re~idue. A diatomaceous earth partition column is prepared using a system com-posed of heptane:ethyl acetate:methanol:water (2000:25:-1000:17). A 120 g. portion of diatomaceous earth and 90 ..
`` 1(3S~3999 1 ml, of lower phase are used for the column. The syr-upy residue, 12 g. of diatomaceous earth and 9 ml. of lower phase are applied to the top of the column. The column is developed with upper phase. Fractions of 10 ml. each are collected. The activity in the fractions is located by thin layer chromatography. Fractions 22-41 are combined and concentrated in vacuo to a residue. The residue is dissolved in 50 ml. of methanol and filtered.
Thç filtrate is warmed on a steam bath, 10 ml. of water is added and the mixture is allowed to cool slowly to 4C.
The resulting crystals are collected giving 566 mg. of ., BL580Q as the p-bromophenacyl ester.
The ~-bromophenacyl ester of BL580~ has micro-analytical data as follows: C, 58.80; H, 7.~0; Br, 8.64;
a specific rotation [~]25 = +63 + 2 (CHC13 at 0.51%).
The ~-bromophenacyl ester of BL580~ exhibited characteristic absorption in the infrared region of the spectrum at the following wavelengths: 2.95; 5.88; 6.30;
8.20; 8.45; 8.60; 9.00; 9.15 (braod); 9.37 (broad); 9.62;
10.06; and 10.37.
The molecular weight of the ~-bromophenacyl ester of BL580~ monohydrate is 1114 + 0.3% as determined by X-ray diffraction.
A standard infrared absorption spectrum of the ~-bromophenacyl ester of BL580~ prepared in a KBr pellet is shown in Figure 7 of the accompanying drawings.
A standard ultraviolet absorption spectrum of the ~-bromophenacyl ester of BL580~ prepared at a concentration of 33.84 mcg./ml. in methanol is shown in Figure 8 of the accompanying drawings.
:. . .
1 A standard proton magnetic resonance spectrum of the p-bromophenacyl ester of BL580~ is shown in Fig-ure 9 ~f the accompanying drawings.
'~ :
! ~
,: ;
;J
P~ 30 ,':
,: , ,~, . . .
. , . , ~ ... ;: :
Claims (2)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for the preparation of antibiotic BL580.DELTA. of the formula:
and the pharmacologically acceptable cationic salts thereof, which comprises cultivating Streptomyces hygroscopicus NRRL
8180 or mutants thereof in an aqueous nutrient medium con-taining assimilable sources of carbohydrate, nitrogen, and inorganic salts under submerged aerobic conditions until substantial antibiotic activity is imparted to said medium, and then recovering antibiotic BL580.DELTA. therefrom.
and the pharmacologically acceptable cationic salts thereof, which comprises cultivating Streptomyces hygroscopicus NRRL
8180 or mutants thereof in an aqueous nutrient medium con-taining assimilable sources of carbohydrate, nitrogen, and inorganic salts under submerged aerobic conditions until substantial antibiotic activity is imparted to said medium, and then recovering antibiotic BL580.DELTA. therefrom.
2. The compound antibiotic BL58.DELTA. of the formula:
whenever prepared according to the process of Claim 1 or by an obvious chemical equivalent thereof.
whenever prepared according to the process of Claim 1 or by an obvious chemical equivalent thereof.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US701,395 | 1976-06-04 | ||
| US70139576A | 1976-06-30 | 1976-06-30 | |
| US05/756,659 US4138481A (en) | 1976-06-30 | 1977-01-04 | Antibiotic BL580Δ and method of use |
| US756,659 | 1977-01-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1093999A true CA1093999A (en) | 1981-01-20 |
Family
ID=27106775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA279,775A Expired CA1093999A (en) | 1976-06-04 | 1977-06-03 | Antibiotic bl580.delta. from streptomyces hygrosicopieus |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPS5356668A (en) |
| AR (1) | AR212717A1 (en) |
| AT (1) | AT358725B (en) |
| AU (1) | AU514519B2 (en) |
| CA (1) | CA1093999A (en) |
| CH (1) | CH636642A5 (en) |
| DD (1) | DD144561A5 (en) |
| DE (1) | DE2728596A1 (en) |
| DK (1) | DK282577A (en) |
| ES (1) | ES460266A1 (en) |
| FR (1) | FR2356667A1 (en) |
| GB (1) | GB1560817A (en) |
| GR (1) | GR73051B (en) |
| IE (1) | IE45349B1 (en) |
| IL (1) | IL52205A (en) |
| IT (1) | IT1079709B (en) |
| NL (1) | NL7707283A (en) |
| NZ (1) | NZ184262A (en) |
| PL (1) | PL105378B1 (en) |
| PT (1) | PT66700B (en) |
| SE (1) | SE7707552L (en) |
| YU (1) | YU156677A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4150152A (en) * | 1977-10-26 | 1979-04-17 | Pfizer Inc. | Polycyclic ether antibiotic produced by a strain of streptomyces hygroscopicus |
| FR3078629B1 (en) | 2018-03-12 | 2020-07-31 | Adisseo France Sas | SAPONIN-BASED FOOD ADDITIVE FOR THE TREATMENT OF COCCIDIOSIS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3812249A (en) * | 1972-11-24 | 1974-05-21 | American Cyanamid Co | Antibiotic bl580 |
| DK133254C (en) * | 1973-03-09 | 1976-09-13 | Sandoz Ag | PROCEDURE FOR THE PREPARATION OF AN ANTIBIOTIC SEPTAMYCIN OR SALTS THEREOF |
| CH579147A5 (en) * | 1973-03-09 | 1976-08-31 | Sandoz Ag | Antiparasitic streptomyces hygroscopicus metabolite - i.e. septamycine, as antibacterials, antiprotozoals, anthelminthics and coccidiostats |
-
1977
- 1977-05-31 IL IL52205A patent/IL52205A/en unknown
- 1977-06-03 CA CA279,775A patent/CA1093999A/en not_active Expired
- 1977-06-03 AU AU25823/77A patent/AU514519B2/en not_active Expired
- 1977-06-08 AR AR267973A patent/AR212717A1/en active
- 1977-06-13 GR GR53684A patent/GR73051B/el unknown
- 1977-06-16 NZ NZ184262A patent/NZ184262A/en unknown
- 1977-06-22 PT PT66700A patent/PT66700B/en unknown
- 1977-06-22 IT IT49930/77A patent/IT1079709B/en active
- 1977-06-24 DE DE19772728596 patent/DE2728596A1/en not_active Withdrawn
- 1977-06-24 DK DK282577A patent/DK282577A/en not_active Application Discontinuation
- 1977-06-24 YU YU01566/77A patent/YU156677A/en unknown
- 1977-06-24 FR FR7719508A patent/FR2356667A1/en active Granted
- 1977-06-28 IE IE1328/77A patent/IE45349B1/en unknown
- 1977-06-28 GB GB27073/77A patent/GB1560817A/en not_active Expired
- 1977-06-29 CH CH800577A patent/CH636642A5/en not_active IP Right Cessation
- 1977-06-29 SE SE7707552A patent/SE7707552L/en not_active Application Discontinuation
- 1977-06-29 AT AT463077A patent/AT358725B/en not_active IP Right Cessation
- 1977-06-30 ES ES460266A patent/ES460266A1/en not_active Expired
- 1977-06-30 JP JP7727877A patent/JPS5356668A/en active Pending
- 1977-06-30 PL PL1977199271A patent/PL105378B1/en unknown
- 1977-06-30 NL NL7707283A patent/NL7707283A/en not_active Application Discontinuation
- 1977-06-30 DD DD77199805A patent/DD144561A5/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IT1079709B (en) | 1985-05-13 |
| IL52205A0 (en) | 1977-07-31 |
| PT66700A (en) | 1977-07-01 |
| IE45349L (en) | 1977-12-30 |
| AT358725B (en) | 1980-09-25 |
| PL199271A1 (en) | 1978-09-11 |
| SE7707552L (en) | 1977-12-31 |
| NZ184262A (en) | 1980-08-26 |
| NL7707283A (en) | 1978-01-03 |
| AU2582377A (en) | 1978-12-07 |
| DD144561A5 (en) | 1980-10-22 |
| YU156677A (en) | 1983-01-21 |
| FR2356667B1 (en) | 1981-12-31 |
| CH636642A5 (en) | 1983-06-15 |
| ATA463077A (en) | 1980-02-15 |
| ES460266A1 (en) | 1978-10-01 |
| DK282577A (en) | 1977-12-31 |
| PL105378B1 (en) | 1979-10-31 |
| GB1560817A (en) | 1980-02-13 |
| IE45349B1 (en) | 1982-08-11 |
| FR2356667A1 (en) | 1978-01-27 |
| DE2728596A1 (en) | 1978-01-12 |
| AU514519B2 (en) | 1981-02-12 |
| AR212717A1 (en) | 1978-09-15 |
| JPS5356668A (en) | 1978-05-23 |
| GR73051B (en) | 1984-01-26 |
| IL52205A (en) | 1980-05-30 |
| PT66700B (en) | 1978-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0026338A1 (en) | Antibiotic C-15003 PHM, production thereof and microorganisms for its production | |
| CA1142866A (en) | Antibiotic a/16686 and process for the preparation thereof | |
| US4559301A (en) | Process for preparing macrocin derivatives | |
| US4138481A (en) | Antibiotic BL580Δ and method of use | |
| US4252898A (en) | Antibiotics A6888C and A6888X | |
| US4384043A (en) | Process for producing the antibiotic nosiheptide | |
| CA1093999A (en) | Antibiotic bl580.delta. from streptomyces hygrosicopieus | |
| GB1563432A (en) | Antitumor anthracycline glycosides | |
| US4189537A (en) | Process of producing antibiotic BL580Δ with Streptomyces hygroscopicus | |
| US4497797A (en) | β-Galactosidase inhibitor GT-2558 and its derivatives | |
| US4152424A (en) | Antibiotic 1745A/X and methods for the production thereof | |
| US3812249A (en) | Antibiotic bl580 | |
| US3992264A (en) | Antibiotic 1745A/X and methods for the production thereof | |
| US4204038A (en) | Process for preparing antibiotics MA 144-M1 and MA 144-M2 | |
| US3932619A (en) | Metabolite A-27106 and processes for its preparation and use | |
| US4358584A (en) | Antibiotics A6888C and A6888X | |
| US4132779A (en) | Antibiotic BL580 Zeta and use thereof as anticoccidial agent | |
| KR870001147B1 (en) | Method for preparing 19-epi-diamine | |
| KR960005150B1 (en) | Novel pyrazine oxide compounds of NF-1616-904 and pharmaceutical compositions containing them | |
| EP0187049A2 (en) | Micromonospora microorganisms and macrolide antibiotic production therewith | |
| US3950516A (en) | Process for preparing cirramycin A1 | |
| EP0058838A1 (en) | Antibiotic LL BO1208 alpha and LL BO1208 beta | |
| EP0046641A2 (en) | Novel antibiotics, the microbiological preparation of antibiotics, and a novel microorganism | |
| US4070376A (en) | Antibiotic 1745A/X and methods for the production thereof | |
| US4656258A (en) | Macrocin derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |